A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

Schizophrenia Clinical Trial

Official title:

An Open-Label, Fixed Sequence, Multiple Dose Study of Glucose and Insulin Associated Parameters: SEP-363856 vs Prior Antipsychotic (PA) Standard of Care in Subjects With Schizophrenia Suffering From Metabolic Dysregulation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05463770
• Other study ID #: SEP361-123
• Status: Completed
• Phase: Phase 1
• Start date: August 30, 2022
• Est. completion date: August 22, 2023

Study information

• Verified date: December 2023
• Source: Sumitomo Pharma America, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia and assess whether it changes: - how the body processes (uses) glucose (blood sugar) - how much insulin the pancreas can make. Insulin is a hormone that lowers blood sugar levels in the body. The information from this study will help to understand any effect the study medication may have on how the body uses and stores glucose. This study is accepting both male and female subjects. It will be held in approximately 6 locations in the United States. Participation could last up to 12 weeks.

Description:

This is an open-label, fixed sequence, multiple dose design. Following screening evaluations, subjects will check-in to the clinical research unit. After confirmation of continuation criteria, subjects will undergo an oral glucose tolerance test (oGTT), mixed meal tolerance test (MMTT) and spirulina breath test (GEBT). After these assessments are completed, subjects will have their prior antipsychotic (PA) or any other medication with psychotropic propensity washed out (dependent on their antipsychotic elimination half-life). Subjects will undergo SEP-363856 titration schedule, followed by the oGTT, MMTT and GEBT tests during the SEP-363856 Stable Dose Period. Subjects will be stabilized on their prior antipsychotic, discharged from the clinical research unit, and return to the unit for the follow-up visit 7 + 2 days after discharge.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: August 22, 2023
• Est. primary completion date: August 22, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria: (this list is not all inclusive)

• Male or female subjects between 18 and 65 years of age, inclusive at time of consent.
• Subject meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a primary diagnosis of schizophrenia as established by clinical interview, using the DSM-5 as a reference and confirmed using the Structured Clinical Interview for DSM-5, Clinical Trials Version [SCID-CT]).
• Subject must have a CGI-S score = 4 (normal to moderately ill) at Screening
• Subject must have a PANSS total score = 80 at Screening and a score of = 4 on the following PANSS items at Screening: P7 (hostility) and G8 (uncooperativeness)
• Subjects' antipsychotic medication at screening must have had no dose change (minor dose adjustments for tolerability purposes are permitted) for at least eight weeks prior to the Screening visit. Exclusion Criteria: (this list is not all inclusive) -- Subject has a DSM-5 diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia or intellectual disability (IQ < 70).
• Subject has attempted suicide within 12 months prior to Screening.
• Subject answers "yes" to "Suicidal Ideation" Items 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS at Screening (ie. in the past 1 month) or at any subsequent C-SSRS assessment prior to dosing (ie, since last visit).
• Subject is at risk of harming him/herself or others according to the Investigator's judgment.

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• SEP-363856
SEP-363856, 12.5 mg, 25 mg, and 50 mg tablets. The dose taken at the same time each day, in the evening and in the morning. Multiple tablets may be required to achieve a single dose.

Locations

Country	Name	City	State
United States	Galiz Research	Hialeah	Florida
United States	Woodland International Research Group, LLC	Little Rock	Arkansas
United States	Collaborative Neuroscience Research, LLC	Long Beach	California
United States	Catalina Research Institute LLC	Montclair	California
United States	Neuro-Behavioral Clinical Research, Inc.	North Canton	Ohio
United States	Pillar Clinical Research, LLC	Richardson	Texas
United States	Woodland Research Northwest, LLC	Rogers	Arkansas
United States	CNRI - San Diego LLC	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Sumitomo Pharma America, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline (PA) in oGTT derived plasma AUC0-120 min of glucose, insulin, c-peptide in oGTT to stable dose (SEP-363856) period assessment.		PA Baseline and SEP-363856 Stable Dose Period (up to 48 days)
Primary	Change from baseline (PA) in mixed meal tolerance test (MMTT) derived plasma AUC0-240 min of glucose, insulin, c-peptide and ß-cell responsivity index to stable dose (SEP-363856) period assessment.		PA Baseline and SEP-363856 Stable Dose Period (up to 48 days)
Secondary	Change from baseline (PA) in plasma AUC0-240 min and Cmax of acetaminophen levels to stable dose (SEP-363856) period assessment.		PA Baseline and SEP-363856 Stable Dose Period (up to 48 days)
Secondary	Change in Cmax of acetaminophen levels to stable dose (SEP-363856) period assessment.		PA Baseline and SEP-363856 Stable Dose Period (up to 48 days)
Secondary	Change in gastric emptying terminal elimination half-life (T1/2), baseline to stable dose (SEP-363856) period assessment.		PA Baseline and SEP-363856 Stable Dose Period (up to 48 days)
Secondary	Change in kPCD, baseline to stable dose (SEP-363856) period assessment		PA Baseline and SEP-363856 Stable Dose Period (up to 48 days)
Secondary	Change in the Visual Analog Scale (VAS) of fullness, hunger and satiety, baseline - repeat test (PA baseline to SEP-363856 stable dose period assessment) for all time points.	Visual Analog Scale (VAS) is on a scale of 0-100, higher represents higher pain intensity (higher score represents worse outcome).	PA Baseline and SEP-363856 Stable Dose Period (up to 48 days)
Secondary	Change in lag time, baseline to stable dose (SEP-363856) period assessment		PA Baseline and SEP-363856 Stalbe Dose Period (up to 48 days)